Nucleic Acid Medicines Buzzing: The 3rd I-RNA Summit on Nucleic Acid Antiviral Drugs and Vaccine Industry Successfully Ended

Nucleic acid therapy, one of the fastest-growing sectors in the biopharmaceutical field in recent years, continues to thrive. The COVID-19 pandemic has particularly propelled nucleic acid drugs, especially mRNA vaccines, to the forefront. In the post-pandemic era, how will mRNA technology further evolve? From expanding into new indications, optimizing manufacturing processes, to scaling up production capacity, and even welcoming the upcoming debut of the first domestically produced small nucleic acid drug, nucleic acid therapy is entering its golden age!

Recently, the I-RNA 3rd Annual Summit on Nucleic Acid Drugs and Vaccine Industry, organized by Shanghai QiuShi Pharmaceutical Consulting Co., Ltd., was held. The summit brought together over 80 industry experts and more than 1200 industry colleagues to discuss core technologies, share the latest achievements, and embark on a new journey towards industrialization of nucleic acid drugs.

At the summit, Mr. Xu Rongsong, CEO of Guangdong Veliter Biomedical Technology Co., Ltd., shared the latest developments in oligonucleotide active pharmaceutical ingredients (APIs), focusing on quality research, process development, and bulk production